A multicenter , retrospective study analyzing clinical outcomes following initial FGFRi treatment in Cholangiocarcinoma harboring FGFR alterations
Latest Information Update: 06 Sep 2022
At a glance
- Drugs Pemigatinib (Primary) ; Antineoplastics; Fibroblast growth factor receptor antagonists
- Indications Cholangiocarcinoma
- Focus Therapeutic Use
Most Recent Events
- 06 Sep 2022 New trial record
- 02 Sep 2022 Results published in the Targeted Oncology